152 related articles for article (PubMed ID: 10953123)
1. Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy.
Fujikawa K; Matsui Y; Miura K; Kobayashi T; Oka H; Fukuzawa S; Takeuchi H
J Urol; 2000 Sep; 164(3 Pt 1):673-5. PubMed ID: 10953123
[TBL] [Abstract][Full Text] [Related]
2. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma.
Fujikawa K; Matsui Y; Oka H; Fukuzawa S; Takeuchi H
J Urol; 1999 Dec; 162(6):1934-7. PubMed ID: 10569541
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
4. Higher Serum C-reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma.
Nakayama T; Saito K; Kumagai J; Nakajima Y; Kijima T; Yoshida S; Kihara K; Fujii Y
Clin Genitourin Cancer; 2018 Dec; 16(6):e1151-e1158. PubMed ID: 30213543
[TBL] [Abstract][Full Text] [Related]
5. Preoperative C-Reactive Protein Values as a Potential Component in Outcome Prediction Models of Metastasized Renal Cell Carcinoma Patients Receiving Cytoreductive Nephrectomy.
Kalogirou C; Mulfinger P; Sokolakis I; Krebs M; Kübler H; Riedmiller H; Vergho D
Urol Int; 2017; 99(3):297-307. PubMed ID: 28624829
[TBL] [Abstract][Full Text] [Related]
6. Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy.
Araki K; Igarashi T; Tobe T; Mizoguchi K; Suzuki H; Furuya Y; Ichikawa T; Nakatsu HO; Ito H
Urology; 2006 Dec; 68(6):1178-82. PubMed ID: 17141843
[TBL] [Abstract][Full Text] [Related]
7. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
[TBL] [Abstract][Full Text] [Related]
8. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.
Johnson TV; Abbasi A; Owen-Smith A; Young A; Ogan K; Pattaras J; Nieh P; Marshall FF; Master VA
J Urol; 2010 Feb; 183(2):480-5. PubMed ID: 20006861
[TBL] [Abstract][Full Text] [Related]
9. Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy.
Tsujino T; Komura K; Matsunaga T; Yoshikawa Y; Takai T; Uchimoto T; Saito K; Tanda N; Oide R; Minami K; Uehara H; Jeong SH; Taniguchi K; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Azuma H
Ann Surg Oncol; 2017 Sep; 24(9):2787-2793. PubMed ID: 28643013
[TBL] [Abstract][Full Text] [Related]
10. Serum immunosuppressive acidic protein in renal cell carcinoma.
Ueda T
Urol Res; 1986; 14(2):101-3. PubMed ID: 3727211
[TBL] [Abstract][Full Text] [Related]
11. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
12. Changes in serum immunosuppressive acidic protein following surgery in patients with renal carcinoma.
Ueda T; Yasumasu T; Uozumi J; Naito S
Br J Urol; 1993 Oct; 72(4):409-12. PubMed ID: 8261296
[TBL] [Abstract][Full Text] [Related]
13. Minor symptoms are suggestive of metastatic renal cell carcinoma if c-reactive protein remains high after curative nephrectomy.
Abbasi A; Johnson TV; Master VA
J Clin Oncol; 2011 Feb; 29(6):e133-4. PubMed ID: 21115862
[No Abstract] [Full Text] [Related]
14. Minimal changes in the systemic immune response after nephrectomy of localized renal masses.
Wald G; Barnes KT; Bing MT; Kresowik TP; Tomanek-Chalkley A; Kucaba TA; Griffith TS; Brown JA; Norian LA
Urol Oncol; 2014 Jul; 32(5):589-600. PubMed ID: 24768357
[TBL] [Abstract][Full Text] [Related]
15. Nomograms incorporating serum C-reactive protein effectively predict mortality before and after surgical treatment of renal cell carcinoma.
Hsiao W; Herrel LA; Yu C; Kattan MW; Canter DJ; Carthon BC; Ogan K; Master VA
Int J Urol; 2015 Mar; 22(3):264-70. PubMed ID: 25428139
[TBL] [Abstract][Full Text] [Related]
16. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma.
Miyata Y; Koga S; Nishikido M; Noguchi M; Kanda S; Hayashi T; Saito Y; Kanetake H
Urology; 2001 Aug; 58(2):161-4. PubMed ID: 11489689
[TBL] [Abstract][Full Text] [Related]
17. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
[TBL] [Abstract][Full Text] [Related]
18. Interferon as adjunctive treatment for non-metastatic renal cell carcinoma.
Takahashi S; Tanigawa T; Imagawa M; Mimata H; Nomura Y; Ogata J
Br J Urol; 1994 Jul; 74(1):11-4. PubMed ID: 8044505
[TBL] [Abstract][Full Text] [Related]
19. Serum immunosuppressive acidic protein as a tumor marker for renal cell carcinoma.
Igarashi T; Murakami S; Isaka S; Okano T; Shimazaki J; Matsuzaki O
Eur Urol; 1991; 19(4):332-5. PubMed ID: 1915542
[TBL] [Abstract][Full Text] [Related]
20. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
